Head-to-head comparison
Tirzepatide vs Retatrutide: 2026 research comparison
Side-by-side comparison of tirzepatide (dual GIP/GLP-1) and retatrutide (triple GIP/GLP-1/glucagon) — receptor profile, Phase 2/3 weight-loss data, safety signals, dosing kinetics, and UK research context.
At a glance
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor profile | Dual GIP / GLP-1 | Triple GIP / GLP-1 / glucagon |
| Developer | Eli Lilly | Eli Lilly |
| UK regulatory status | MHRA-licensed (Mounjaro / Zepbound) | Not approved — research only |
| Mean weight reduction (Phase 3 / Phase 2 highest dose) | ≈22% at 72w (SURMOUNT-1, 15 mg) | ≈24% at 48w (Phase 2, 12 mg) |
| Dosing frequency | Once weekly | Once weekly |
| Half-life | ≈5 days | ≈6 days |
| Glycaemic control | Robust HbA1c reduction (SURPASS) | Robust glycaemic reduction in Phase 2 |
| Notable side-effect signal | GI (nausea, diarrhoea) | GI plus modest HR increase in Phase 2 |
Receptor pharmacology
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor through a single 39-amino-acid backbone with a fatty-acid side chain for albumin binding. The dual mechanism is now understood to produce more than additive metabolic effects — GIP signalling appears to potentiate GLP-1-driven satiety while contributing independently to adipocyte biology.
Retatrutide extends this concept by adding a third receptor — glucagon — to the agonist profile. Hepatic glucagon signalling increases energy expenditure and accelerates lipolysis; combining this with incretin signalling theoretically attacks adipose stores from both the energy-intake and energy-expenditure sides simultaneously. The Phase 2 data published in NEJM (2023) supports this hypothesis: mean weight reductions in the 12 mg arm at 48 weeks exceeded what tirzepatide achieved at 72 weeks in SURMOUNT-1, despite a shorter treatment duration.
Clinical evidence base
The evidence asymmetry is the most important point for any researcher comparing these compounds. Tirzepatide has a complete Phase 3 evidence package across both diabetes (SURPASS-1 through 5) and obesity (SURMOUNT-1 through 4), plus the SURMOUNT-MMO cardiovascular outcomes trial in progress. Retatrutide's most-cited dataset is a single Phase 2 trial (Jastreboff et al., NEJM 2023) with 338 participants over 48 weeks. The Phase 3 programme (TRIUMPH-1 through 4) was initiated in 2023 with first readouts expected from 2025 onwards.
Safety signals
Both compounds share the GLP-1-class gastrointestinal profile (nausea, diarrhoea, constipation, decreased appetite) that drives the majority of dose-related discontinuations. The retatrutide Phase 2 trial flagged a small heart-rate increase (3-6 bpm in the 8 mg and 12 mg arms) that has not been seen with tirzepatide; whether this is glucagon-receptor related and whether it persists at steady-state remains an open question for Phase 3.
Which to prioritise in a literature review
For UK researchers reviewing the incretin class in 2026: tirzepatide remains the benchmark, with the deepest evidence base, established MHRA licensure (as Mounjaro for type 2 diabetes and Zepbound for obesity in select markets), and the strongest safety dossier. Retatrutide is the compound to watch — early efficacy data is the most impressive yet seen in incretin pharmacology — but the regulatory and safety file will not be comparable until at least the late-2020s.
See also: Tirzepatide full profile · Retatrutide full profile · Retatrutide Phase 2 NEJM summary.